title: Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.
authors.forename: Valeria A S
authors.initials: VA
authors.lastname: De Melo
authors.forename: Dragana
authors.initials: D
authors.lastname: Milojkovic
authors.forename: Jamshid S
authors.initials: JS
authors.lastname: Khorashad
authors.forename: David
authors.initials: D
authors.lastname: Marin
authors.forename: John M
authors.initials: JM
authors.lastname: Goldman
authors.forename: Jane F
authors.initials: JF
authors.lastname: Apperley
authors.forename: Alistair G
authors.initials: AG
authors.lastname: Reid
mesh_terms: D002869:Chromosome Aberrations / Q000187:drug effects*; D002999:Clone Cells; D000069439:Dasatinib; D006410:Hematopoiesis / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D010677:Philadelphia Chromosome; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib